Brammer Bio seeking tax increment financing for proposed new manufacturing site in Massachusetts

DNA genomics precision medicine
Brammer Bio, a unit of Thermo Fisher Scientific, is seeking tax increment financing for a proposed new manufacturing facility in Norton, Massachusetts. (Pixabay)

Brammer Bio, which was acquired by Thermo Fisher Scientific earlier this year, is seeking tax increment financing for a proposed new manufacturing facility in Norton, Massachusetts.

Brammer Bio, which provides development and manufacturing services for cell and gene therapies, will ask for a TIF agreement in a meeting of residents scheduled for Aug. 26.

Details of the TIF are still being worked out, Town Manager Michael Yunits told The Sun Chronicle.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company, which employs about 600 people in other locations, expects to employ about 300 people in Norton by 2021, according to the newspaper.

Ron O’Brien, a spokesman for Thermo Fisher, told FiercePharmaManufacturing that the project is still in a preliminary stage and additional information such as size and projected cost will be released in the near future.

In recent years, Alnylam Pharmaceuticals built a $200 million, 200,000-square-foot facility in Norton’s industrial park near Taunton.

Thermo Fisher, a CDMO, announced in March that it was buying Brammer Bio for $1.7 billion as part of an effort to expand its presence in the growing gene therapies market. At the time of the announcement, Brammer Bio, which is based in Cambridge, said it expected to produce $150 million in revenue this year and outpace the market growth rate of 25% for the midterm. Thermo Fisher said it expected the acquisition to add about $0.10 per share in the first full year of ownership.

With the growth of gene therapies, many biotechs have begun to invest in building their own specialized manufacturing facilities as well as looking to CDMOs for additional capacity. Last year, CDMO leader Lonza opened a 300,000-square-foot facility in a Houston suburb that it touts as the largest dedicated cell-and-gene-therapy manufacturing facility in the world.

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.